Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24344882 | 1.00 | RORC (0.32) | RORCCETPOPRL1 | |
| SCHEMBL30623312 | 0.87 | RORC (0.35) | RORCOPRL1 | |
| SCHEMBL26064336 | 0.87 | RORC (0.35) | RORCOPRL1 | |
| SCHEMBL31387344 | 0.87 | RORC (0.35) | RORCOPRL1 | |
| SCHEMBL29413710 | 0.86 | — | — | |
| SCHEMBL24346287 | 0.83 | OPRL1 (0.33) | OPRL1 | |
| SCHEMBL29413701 | 0.83 | OPRL1 (0.33) | OPRL1 | |
| SCHEMBL24346285 | 0.80 | OPRL1 (0.38) | RORCOPRL1 | |
| SCHEMBL29413685 | 0.80 | OPRL1 (0.38) | RORCOPRL1 | |
| SCHEMBL30623265 | 0.78 | JAK2 (0.34) | RORCOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2024-11-07 | — | — | US | disclosed |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4204423-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022047031-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | RORC 3725/4885CETP 439/4885OPRL1 453/4885 |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | RORC 3725/4885CETP 439/4885OPRL1 453/4885 |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | RORC 3725/4885CETP 439/4885OPRL1 453/4885 |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | RORC 3725/4885CETP 439/4885OPRL1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.